Community Statement from Novartis Gene Therapies: Zolgensma Safety Monitoring Update on Acute Liver Failure
Novartis Gene Therapies has just recently issued a community update about two acute liver failure cases in Russia and Kazakhstan reported back in August 2022.
While deeply touched by what had happened, we have tried, on behalf of the SMA Europe Community, to get more information as soon as the news was released. Only now Novartis sends us the official statement that we can share on our communication channels.
We hope that, in the future, Novartis Gene Therapy will be able to deliver such relevant information much faster to communicate this to SMA Europe Community as soon as it is possible.